Design and synthesis of piperidine-containing sphingoid base analogues

Journal of Organic Chemistry

Volumn 74, Issue 10, 2009, Pages 3900-3904

  Cho, Jihee ^a   Yun, Mi Lee ^a   Kim, Deukjoon ^a   Kim, Sanghee ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO GROUP; BIOLOGICAL EVALUATION; CANCER CELL GROWTH; CARBON ATOMS; CHEMICAL EQUATIONS; EFFICIENT SYNTHESIS; METATHESIS REACTIONS; SPHINGOID BASIS; SYNTHESIS FEATURES;

AMINES; GROWTH KINETICS;

SYNTHESIS (CHEMICAL);

2 (HYDROXYMETHYL) 4 TETRADECYLIDENEPIPERIDIN 3 OL; 2 (HYDROXYMETHYL) 4 TETRADECYLPIPERIDIN 3 OL; ALKADIENE; CARBON; PIPERIDINE DERIVATIVE; SPHINGOSINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG CONFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; RING CLOSING METATHESIS; STEREOCHEMISTRY;

DRUG DESIGN; MOLECULAR CONFORMATION; PIPERIDINES; SPHINGOSINE;

EID: 65949110846     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo900378h     Document Type: Article

References (50)

1. (a) Wermuth, C. G., Ed. The Practice of Medicinal Chemistry, 3rd ed.; Academic Press: San Diego, 2008.
2. (b) Silverman, R. B. The Organic Chemistry of Drug Design and Drug Action, 2nd ed.; Academic Press: San Diego, 2004.
3. Kolter, T. In Highlights in Bioorganic Chemistry: Methods and Applications; Schmuck, C., Wennemers, H., Ed.; Wiley-VCH: Weinheim, 2004; Chapter 1.4, p 48.
4. Howell, A. R.; Ndakala, A. J. Curr. Org. Chem. 2002, 6, 365.
5. (a) Li, L.; Tang, X.; Taylor, K. G.; DuPré, D. B.; Yappert, M. C. Biophys. J. 2002, 82, 2067.
6. (b) DuPré, D. B.; Yappert, M. C. J. Mol. Struct. THEOCHEM 1999, 467, 115, and references therein.
7. Kuroda, I.; Musman, M.; Ohtani, I. I.; Ichiba, T.; Tanaka, J.; Gravalos, D. G.; Higa, T. J. Nat. Prod. 2002, 65, 1505.
8. Kobayashi, J.; Cheng, J.-F.; Ishibashi, M.; Wälchli, M. R.; Yamamura, S.; Ohizumi, Y. J. Chem. Soc., Perkin Trans. I 1991, 1135.
9. For representative examples, see: (a) Fuhshuku, K.; Hongo, N.; Tashiro, T.; Masuda, Y.; Nakagawa, R.; Seino, K.; Taniguchi, M.; Mori, K. Bioorg. Med. Chem. 2008, 16, 950.
10. (b) Zhu, R.; Snyder, A. H.; Kharel, Y.; Schaffter, L.; Sun, Q.; Kennedy, P. C.; Lynch, K. R.; Macdonald, T. L. J. Med. Chem. 2007, 50, 6428.
11. (c) Hanessian, S.; Charron, G.; Billich, A.; Guerini, D. Bioorg. Med. Chem. Lett. 2007, 17, 491.
12. (d) Wascholowski, V.; Giannis, A. Angew. Chem., Int. Ed. 2006, 45, 827.
13. (e) Dougherty, A. M.; McDonald, F. E.; Liotta, D. C.; Moody, S. J.; Pallas, D. C.; Pack, C. D.; Merrill, A. H. Org. Lett. 2006, 8, 649.
14. (f) Ha, H.-J.; Hong, M. C.; Ko, S. W.; Kim, Y. W.; Lee, W. K.; Park, J. Bioorg. Med. Chem. Lett. 2006, 16, 1880.
15. (g) Macchia, M.; Barontini, S.; Bertini, S.; Bussolo, V. D.; Fogli, S.; Giovannetti, E.; Grossi, E.; Minutolo, F.; Danesi, R. J. Med. Chem. 2001, 44, 3994.
16. For reviews of enyne metathesis, see: (a) Villar, H.; Frings, M.; Bolm, C. Chem. Soc. Rev. 2007, 36, 55.
17. (b) Diver, S. T.; Giessert, A. J. Chem. Rev. 2004, 104, 1317. For reviews of cross metathesis, see:
18. (c) Grubbs, R. H. Tetrahedron 2004, 60, 7117.
19. (d) Connon, S. J.; Blechert, S. Angew. Chem., Int. Ed. 2003, 42, 1900.
20. For representative examples, see: (a) Kummer, D. A.; Brenneman, J. B.; Martin, S. F. Org. Lett. 2005, 7, 4621.
21. (b) Royer, F.; Vilain, C.; Elkaïm, L.; Grimaud, L. Org. Lett. 2003, 5, 2007.
22. (c) Lee, H.-Y.; Kim, H. Y.; Tae, H.; Kim, B. G.; Lee, J. Org. Lett. 2003, 5, 3439.
23. (a) McDonald, F. E.; Gleason, M. M. J. Am. Chem. Soc. 1996, 118, 6648.
24. (b) Oehlschlager, A. C.; Czyzewska, E. Tetrahedron Lett. 1983, 24, 5587.
25. Marino, J. P.; Nguyen, H. N. J. Org. Chem. 2002, 67, 6841.
26. The enantiopurity was determined by chiral HPLC analysis of its benzoate derivative.
27. For a similar transformation, see: (a) Martín, R.; Murruzzu, C.; Pericàs, M. A.; Riera, A. J. Org. Chem. 2005, 70, 2325.
28. (b) Torssell, S.; Somfai, P. Org. Biomol. Chem. 2004, 2, 1643.
29. (c) Roush, W. R.; Adam, M. A. J. Org. Chem. 1985, 50, 3752.
30. Smulik, J. A.; Diver, S. T. Org. Lett. 2000, 2, 2271.
31. (a) Tong, R.; Valentine, J. C.; McDonald, F. E.; Cao, R.; Fang, X.; Hardcastle, K. I. J. Am. Chem. Soc. 2007, 129, 1050.
32. (b) Chandiran, T.; Vancheesan, S. J. Mol. Catal. 1994, 88, 31.
33. (c) Takahashi, A.; Kirio, Y.; Sodeoka, M.; Sasai, H.; Shibasaki, M. J. Am. Chem. Soc. 1989, 111, 643.
34. (d) Shibasaki, M.; Sodeoka, M.; Ogawa, Y. J. Org. Chem. 1984, 49, 4096.
35. (a) Rossiter, B. E.; Verhoeven, T. R.; Sharpless, K. B. Tetrahedron Lett. 1979, 20, 4733.
36. (b) Itoh, T.; Jitsukawa, K.; Kaneda, K.; Teranishi, S. J. Am. Chem. Soc. 1979, 101, 159.
37. (c) Tanaka, S.; Yamamoto, H.; Nozaki, H.; Sharpless, K. B.; Michaelson, R. C.; Cutting, J. D. J. Am. Chem. Soc. 1974, 96, 5254.
38. (a) Jogireddy, R.; Maier, M. E. J. Org. Chem. 2006, 71, 6999.
39. (b) Hatakeyama, S.; Yoshida, M.; Esumi, T.; Iwabuchl, Y.; lrle, H.; Kawmoto, T.; Yamada, H.; Nishizawa, M. Tetrahedron Lett. 1997, 38, 7887.
40. (c) Hatakeyama, S.; Sugawara, K.; Takano, S. Tetrahedron Lett. 1991, 32, 4513.
41. N2′ reduction of vinyloxirane, see: (a) Ueki, H.; Chiba, T.; Kitazume, T. J. Org. Chem. 2006, 71, 3506.
42. (b) Werner, F.; Parmentier, G.; Luu, B. Tetrahedron 1996, 52, 5525.
43. (c) Molander, G. A.; Belle, B. E. L.; Hahn, G. J. Org. Chem. 1986, 51, 5259.
44. (d) Lenox, R. S.; Katzenellenbogen, J. A. J. Am. Chem. Soc. 1973, 95, 957.
45. Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. J. Am. Chem. Soc. 1991, 113, 4092. See Supporting Information.
46. Kim, S.; Kim, Y. J.; Ahn, K. H. Tetrahedron Lett. 1983, 24, 3369.
47. (a) Yadav, J. S.; Geetha, V.; Raju, A. K.; Gnaneshwar, D.; Chandrasekhar, S. Tetrahedron Lett. 2003, 44, 2983.
48. (b) Wakita, H.; Nishimura, K.; Takigawa, M. J. Invest. Dermatol. 1992, 99, 617.
49. (a) Nagahara, Y.; Shinomiya, T.; Kuroda, S.; Kaneko, N.; Nishio, R.; Ikekita, M. Cancer Sci. 2005, 96, 83.
50. (b) Ahn, E. H.; Schroeder, J. J. Exp. Biol. Med. 2002, 227, 345.